157 related articles for article (PubMed ID: 34439386)
1. Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia.
Abdelmalak R; Lythgoe MP; Evans J; Flynn M; Waters J; Webb A; Pinato DJ; Sharma R
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439386
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
3. Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas.
Lamarca A; Walter T; Pavel M; Borbath I; Freis P; Nuñez B; Childs A; McNamara MG; Hubner RA; Garcia-Carbonero R; Meyer T; Valle JW; Barriuso J
J Natl Cancer Inst; 2017 Jan; 109(5):. PubMed ID: 28130474
[TBL] [Abstract][Full Text] [Related]
4. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract][Full Text] [Related]
5. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.
Centonze G; Maisonneuve P; Prinzi N; Pusceddu S; Albarello L; Pisa E; Barberis M; Vanoli A; Spaggiari P; Bossi P; Cattaneo L; Sabella G; Solcia E; La Rosa S; Grillo F; Tagliabue G; Scarpa A; Papotti M; Volante M; Mangogna A; Del Gobbo A; Ferrero S; Rolli L; Roca E; Bercich L; Benvenuti M; Messerini L; Inzani F; Pruneri G; Busico A; Perrone F; Tamborini E; Pellegrinelli A; Kankava K; Berruti A; Pastorino U; Fazio N; Sessa F; Capella C; Rindi G; Milione M
Neuroendocrinology; 2023; 113(4):457-469. PubMed ID: 36417840
[TBL] [Abstract][Full Text] [Related]
7. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
8. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of inflammation-based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy.
Asama H; Suzuki R; Takagi T; Sugimoto M; Konno N; Watanabe K; Nakamura J; Kikuchi H; Takasumi M; Sato Y; Irie H; Hikichi T; Ohira H
Mol Clin Oncol; 2018 Oct; 9(4):408-414. PubMed ID: 30233794
[TBL] [Abstract][Full Text] [Related]
10. Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual.
Deng BY; Yang M; Wen JY; Hou SZ; Chen Y; Tian BL; Liu XB; Zhang Y
Medicine (Baltimore); 2020 Jan; 99(3):e18736. PubMed ID: 32011453
[TBL] [Abstract][Full Text] [Related]
11. Appraisal of inflammation-based prognostic scores in patients with unresectable perihilar cholangiocarcinoma.
Okuno M; Ebata T; Yokoyama Y; Igami T; Sugawara G; Mizuno T; Yamaguchi J; Nagino M
J Hepatobiliary Pancreat Sci; 2016 Oct; 23(10):636-642. PubMed ID: 27474781
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database.
Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ
Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023
[TBL] [Abstract][Full Text] [Related]
13. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.
Alese OB; Jiang R; Shaib W; Wu C; Akce M; Behera M; El-Rayes BF
Oncologist; 2019 Jul; 24(7):911-920. PubMed ID: 30482824
[TBL] [Abstract][Full Text] [Related]
14. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.
Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
Eur Arch Otorhinolaryngol; 2020 Aug; 277(8):2341-2347. PubMed ID: 32239313
[TBL] [Abstract][Full Text] [Related]
15. Staging the Tumor and Staging the Host: Pretreatment Combined Neutrophil Lymphocyte Ratio and Modified Glasgow Prognostic Score Is Associated with Overall Survival in Patients with Esophagogastric Cancers Undergoing Treatment with Curative Intent.
McSorley ST; Lau HYN; McIntosh D; Forshaw MJ; McMillan DC; Crumley AB
Ann Surg Oncol; 2021 Feb; 28(2):722-731. PubMed ID: 32892266
[TBL] [Abstract][Full Text] [Related]
16. Survivals of patients with surgically treated and High-grade pancreatic neuroendocrine carcinomas: A comparative study between two American Joint Committee on Cancer 8th tumor-node-metastasis staging systems.
Yang M; Zhang Y; Zeng L; Ke NW; Tan CL; Tian BL; Xiang B; Liu XB
Eur J Surg Oncol; 2019 Jun; 45(6):1054-1060. PubMed ID: 30661921
[TBL] [Abstract][Full Text] [Related]
17. Toxicities, safeties and clinical response of dacarbazine-based chemotherapy on neuroendocrine tumors in Taiwan population.
Chiu HY; Lin LY; Chou WC; Fang WL; Shyr YM; Yeh YC; Mu-Hsin Chang P; Chen MH; Hung YP; Chao Y; Chien SH; Chen MH
J Chin Med Assoc; 2018 May; 81(5):423-428. PubMed ID: 29287706
[TBL] [Abstract][Full Text] [Related]
18. Elevated inflammatory parameters and inflammation scores are associated with poor prognosis in patients undergoing pulmonary metastasectomy for colorectal cancer.
Ghanim B; Schweiger T; Jedamzik J; Glueck O; Glogner C; Lang G; Klepetko W; Hoetzenecker K
Interact Cardiovasc Thorac Surg; 2015 Nov; 21(5):616-23. PubMed ID: 26242317
[TBL] [Abstract][Full Text] [Related]
19. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M
Gynecol Oncol; 2018 Jan; 148(1):36-41. PubMed ID: 29107348
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathological classification and prognostic factors of gastrointestinal neuroendocrine neoplasms: an analysis of 119 cases].
Ma X; Zhao W; Zhuang C; Wang X; Tu L; Wang M; Sun Y; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):997-1001. PubMed ID: 28900989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
